Show simple item record

dc.contributor.authorBorden, Ernest C.
dc.contributor.authorAsh, Arlene S.
dc.contributor.authorEnterline, Horatio T.
dc.contributor.authorRosenbaum, Charles
dc.contributor.authorLaucius, J. Frederick
dc.contributor.authorPaul, Anthony R.
dc.contributor.authorFalkson, Geoffrey
dc.contributor.authorLerner, Harvey
dc.date2022-08-11T08:10:41.000
dc.date.accessioned2022-08-23T17:16:48Z
dc.date.available2022-08-23T17:16:48Z
dc.date.issued1982-08-01
dc.date.submitted2010-07-01
dc.identifier.citationAm J Clin Oncol. 1982 Aug;5(4):417-20. <a href="http://journals.lww.com/amjclinicaloncology/Abstract/1982/08000/Phase_II_evaluation_of_dibromodulcitol,_ICRF_159,.12.aspx">Link to article on publisher's site</a>
dc.identifier.issn0277-3732 (Linking)
dc.identifier.pmid6956236
dc.identifier.urihttp://hdl.handle.net/20.500.14038/47481
dc.description.abstractPatients with objectively measurable soft tissue sarcomas, osteosarcomas, chondrosarcomas, and mesotheliomas were treated with dibromodulcitol (DBD) (180 mg/m2 p.o. days 1-10 q4 wks.). ICRF-159 (300 mg/m2 p.o. tid days 1-3 q4 wks), or maytansine (MAYT) (1.5 mg/m2 I.V. q3 wks.). Forty-five evaluable patients received DBD, 47 MAYT, and 37 ICRF-159. Only patients who had had their histopathologic diagnoses confirmed by a pathology reference panel were included in the final analysis. Two patients had objective partial responses: a patient with osteosarcoma who responded to DBD and a patient with fibrosarcoma who had a partial response of brief duration to ICRF-159. Approximately 70% of the patients treated with each drug were of ECOG performance status 0 or 1, and over half had moderate or worse toxicity. It seems unlikely that these drugs have significant therapeutic activity for common mesenchymal malignancies.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=6956236&dopt=Abstract">Link to Article in PubMed</a>
dc.relation.urlhttp://journals.lww.com/amjclinicaloncology/Abstract/1982/08000/Phase_II_evaluation_of_dibromodulcitol,_ICRF_159,.12.aspx
dc.subjectAdolescent
dc.subjectAdult
dc.subjectAged
dc.subjectBone Neoplasms
dc.subjectDrug Evaluation
dc.subjectFemale
dc.subjectHumans
dc.subjectMale
dc.subjectMaytansine
dc.subjectMesothelioma
dc.subjectMiddle Aged
dc.subjectMitolactol
dc.subjectOsteosarcoma
dc.subjectOxazines
dc.subjectPiperazines
dc.subjectPrognosis
dc.subjectRandom Allocation
dc.subjectRazoxane
dc.subjectSarcoma
dc.subjectSoft Tissue Neoplasms
dc.subjectBiostatistics
dc.subjectEpidemiology
dc.subjectHealth Services Research
dc.titlePhase II evaluation of dibromodulcitol, ICRF-159, and maytansine for sarcomas
dc.typeJournal Article
dc.source.journaltitleAmerican journal of clinical oncology
dc.source.volume5
dc.source.issue4
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/qhs_pp/618
dc.identifier.contextkey1378763
html.description.abstract<p>Patients with objectively measurable soft tissue sarcomas, osteosarcomas, chondrosarcomas, and mesotheliomas were treated with dibromodulcitol (DBD) (180 mg/m2 p.o. days 1-10 q4 wks.). ICRF-159 (300 mg/m2 p.o. tid days 1-3 q4 wks), or maytansine (MAYT) (1.5 mg/m2 I.V. q3 wks.). Forty-five evaluable patients received DBD, 47 MAYT, and 37 ICRF-159. Only patients who had had their histopathologic diagnoses confirmed by a pathology reference panel were included in the final analysis. Two patients had objective partial responses: a patient with osteosarcoma who responded to DBD and a patient with fibrosarcoma who had a partial response of brief duration to ICRF-159. Approximately 70% of the patients treated with each drug were of ECOG performance status 0 or 1, and over half had moderate or worse toxicity. It seems unlikely that these drugs have significant therapeutic activity for common mesenchymal malignancies.</p>
dc.identifier.submissionpathqhs_pp/618
dc.contributor.departmentDepartment of Quantitative Health Sciences
dc.source.pages417-20


This item appears in the following Collection(s)

Show simple item record